Abstract
Erythropoietin (Epo) has a long-lasting history as the hormon that allows production of red blood cells. It is now well established that, besides erythropoiesis, Epo has the ability to sustain proliferation of myeloid lineages. More recently, extra-haematological roles have been described for Epo. Its receptor, EpoR, has been detected at the membrane of several neoplastic and normal cell types from the central nervous system and other non haematological cell lines. Whereas Epo-EpoR have been detected several years ago in some extra-haematological normal lineages, their role has long been underestimated whereas they may be crucial for proliferation and survival. Consequently, efforts have recently increased to identify the precise role of Epo-EpoR in a variety of cell types. This allowed identification of physiologically relevant targets that led to original therapeutic strategies.
Keywords: Erythropoietin, neuroprotection, apoptosis, central nervous system, endothelium
Cardiovascular & Hematological Disorders-Drug Targets
Title: Extra-Hematopoietic Effects of Erythropoietin
Volume: 8 Issue: 3
Author(s): Alain Cariou, Stephanie Andre and Yann-Erick Claessens
Affiliation:
Keywords: Erythropoietin, neuroprotection, apoptosis, central nervous system, endothelium
Abstract: Erythropoietin (Epo) has a long-lasting history as the hormon that allows production of red blood cells. It is now well established that, besides erythropoiesis, Epo has the ability to sustain proliferation of myeloid lineages. More recently, extra-haematological roles have been described for Epo. Its receptor, EpoR, has been detected at the membrane of several neoplastic and normal cell types from the central nervous system and other non haematological cell lines. Whereas Epo-EpoR have been detected several years ago in some extra-haematological normal lineages, their role has long been underestimated whereas they may be crucial for proliferation and survival. Consequently, efforts have recently increased to identify the precise role of Epo-EpoR in a variety of cell types. This allowed identification of physiologically relevant targets that led to original therapeutic strategies.
Export Options
About this article
Cite this article as:
Cariou Alain, Andre Stephanie and Claessens Yann-Erick, Extra-Hematopoietic Effects of Erythropoietin, Cardiovascular & Hematological Disorders-Drug Targets 2008; 8 (3) . https://dx.doi.org/10.2174/187152908785849143
DOI https://dx.doi.org/10.2174/187152908785849143 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular disease management through restrained inflammatory responses
Current Pharmaceutical Design Atheroma Burden and Morphology in Women
Current Pharmaceutical Design A Coadunation of Biological and Mathematical Perspectives on the Pandemic COVID-19: A Review
Coronaviruses Diabetes Mellitus in Saudi Arabia: A Review of the Recent Literature
Current Diabetes Reviews Leptin- and Leptin Receptor-Deficient Rodent Models: Relevance for Human Type 2 Diabetes
Current Diabetes Reviews Insulin Resistance in the Early Stages of Renal Failure: Implications for Cardiovascular Risk
Current Diabetes Reviews Editorial (Thematic Issue: Pharmacologic Strategies with Afterload Reduction in Low Cardiac Output Syndrome After Pediatric Cardiac Surgery)
Current Vascular Pharmacology Novel Therapeutic Strategy in the Management of COPD: A Systems Medicine Approach
Current Medicinal Chemistry Nitric Oxide-Mediated Endothelial Dysfunction - Is there Need to Treat?
Current Vascular Pharmacology Review on Bosentan, A Dual Endothelin Receptor Antagonist for the Treatment of Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology Macrophages: Promising Targets for the Treatment of Atherosclerosis
Current Vascular Pharmacology Effect of Gender on Main Clinical Chemistry Parameters in Aged Rats
Current Aging Science Dysglycemia and Abdominal Obesity
Current Vascular Pharmacology Cellular Localisation of Chromogranins and Processed Products in the Diffuse Neuroendocrine System and Related Tumours
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Ethnic Differences in Pharmacogenetically Relevant Genes
Current Drug Targets Oxidative Stress and Pathophysiology of Ischemic Stroke: Novel Therapeutic Opportunities
CNS & Neurological Disorders - Drug Targets Is there an Association Between Periodontitis and Atherosclerosis in Adults? A Systematic Review
Current Vascular Pharmacology The Predictive Value of Lipid Markers in Vascular Disease
Current Pharmaceutical Design ENaC Regulation by Proteases and Shear Stress
Current Molecular Pharmacology